SONN(Delisted)
SonnetยทNASDAQ
--
--(--)
SONN Profile
Sonnet Biotherapeutics Holdings, Inc.
A biopharmaceutical company that develops innovative targeted biologic drugs
100 Overlook Center, Suite 102, Princeton, NJ 08540
--
Sonnet BioTherapeutics Holdings, Inc., was incorporated under the laws of the State of Delaware on October 21, 1999. The company is a clinical biopharmaceutical company with a patented technology for the development of novel biopharmaceuticals called FHAB (Complete Human Albumin Binding). FHAB utilizes a fully human single-chain antibody fragment (scFv), linked to one or two therapeutic molecules, capable of affecting a single or bispecific mechanism of action. The FHAB structure contains a domain designed to bind to human serum albumin (HSA) and "free ride" for transport to targets such as solid tumors or the lymphatic system. The company designed the structure to promote the accumulation of the drug in specific tissues and prolong the duration of activity in the body. FHAB development candidate cells are produced in mammalian cell culture to glycosylate, thereby reducing the risk of immunogenicity. The company's FHAB technology is well suited for future drug development in the field of human diseases, including oncology, autoimmune, pathogenic, inflammatory and hematological diseases.
